Abstract
This article highlights the pricing and reimbursement approval process in France. A product approved on the grounds of its safety, quality, and efficacy cannot be launched before it has passed, and been approved by, the Transparency Commission and a price has been agreed upon with the Pricing Committee. The reimbursement dossier is usually submitted to the Transparency Commission after the license has been obtained. These two committees, and how they make pricing and reimbursement decisions, are detailed. It is expected that both pricing and reimbursement decisions in France will become more stringent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
